Potential lung attack and lethality generated by EpCAM-specific CAR-T cells in immunocompetent mouse models

References

• Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507–11. doi:10.1056/NEJMoa1407222.
   PubMed Web of Science ®Google Scholar
• Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M, Shah NN, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385:517–528. doi:10.1016/S0140-6736(14)61403-3.
   PubMed Web of Science ®Google Scholar
• Park JH, Geyer MB, Brentjens RJ. CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date. Blood. 2016;127:3312–3320. doi:10.1182/blood-2016-02-629063.
   PubMed Web of Science ®Google Scholar
• Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, Sommermeyer D, Melville K, Pender B, Budiarto TM, et al. CD19 CAR-T cells of defined CD4+: CD8+composition in adult B cell ALL patients. J Clin Invest. 2016;126:2123–2138. doi:10.1172/JCI85309.
   PubMed Web of Science ®Google Scholar
• Gardner RA, Finney O, Annesley C, Brakke H, Summers C, Leger K, Bleakley M, Brown C, Mgebroff S, Kelly-Spratt KS, et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood. 2017;129:3322–3331. doi:10.1182/blood-2017-02-769208.
   PubMed Web of Science ®Google Scholar
• Administration TUSFaD. FDA approves CAR-T cell therapy to treat adults with certain types of large B-cell lymphoma. The U.S. Food and Drug Administration: The U.S. Food and Drug Administration; 2017.
   Google Scholar
• Administration TUSFaD. FDA approves tisagenlecleucel for adults with relapsed or refractory large B-cell lymphoma. The U.S. Food and Drug Administration: The U.S. Food and Drug Administration; 2018.
   Google Scholar
• Lamers CH, Klaver Y, Gratama JW, Sleijfer S, Debets R. Treatment of metastatic renal cell carcinoma (mRCC) with CAIX CAR-engineered T-cells-a completed study overview. Biochem Soc Trans. 2016;44:951–959. doi:10.1042/BST20160037.
   PubMed Web of Science ®Google Scholar
• Lamers CH, Sleijfer S, van Steenbergen S, van Elzakker P, van Krimpen B, Groot C, Vulto A, den Bakker M, Oosterwijk E, Debets R, et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol Ther. 2013;21:904–912. doi:10.1038/mt.2013.17.
   PubMed Web of Science ®Google Scholar
• Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010; 18:843–851.
   Google Scholar
• Norelli M, Camisa B, Barbiera G, Falcone L, Purevdorj A, Genua M, Sanvito F, Ponzoni M, Doglioni C, Cristofori P, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018;24:739–748. doi:10.1038/s41591-018-0036-4.
   PubMed Web of Science ®Google Scholar
• Giavridis T, van der Stegen SJC, Eyquem J, Hamieh M, Piersigilli A, Sadelain M. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med. 2018;24:731–738. doi:10.1038/s41591-018-0041-7.
   PubMed Web of Science ®Google Scholar
• Wegner A. Chimeric antigen receptor T cells for the treatment of cancer and the future of preclinical models for predicting their toxicities. Immunotherapy. 2017;9:669–680. doi:10.2217/imt-2017-0028.
   PubMed Web of Science ®Google Scholar
• Siegler EL, Wang P. Preclinical Models in Chimeric Antigen Receptor-Engineered T-Cell Therapy. Hum Gene Ther. 2018;29:534–546. doi:10.1089/hum.2017.243.
   PubMed Web of Science ®Google Scholar
• Ishikawa F, Yasukawa M, Lyons B, Yoshida S, Miyamoto T, Yoshimoto G, Watanabe T, Akashi K, Shultz LD, Harada M, et al. Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain(null) mice. Blood. 2005;106:1565–1573. doi:10.1182/blood-2005-02-0516.
   PubMed Web of Science ®Google Scholar
• Leonard WJ. Cytokines and immunodeficiency diseases. Nat Rev Immunol. 2001;1:200–208. doi:10.1038/35105066.
   PubMed Web of Science ®Google Scholar
• Kovanen PE, Leonard WJ. Cytokines and immunodeficiency diseases: critical roles of the gamma(c)-dependent cytokines interleukins 2, 4, 7, 9, 15, and 21, and their signaling pathways. Immunol Rev. 2004;202:67–83. doi:10.1111/j.0105-2896.2004.00203.x.
   PubMed Web of Science ®Google Scholar
• Trzpis M, McLaughlin PM, de Leij LM, Harmsen MC. Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule. Am J Pathol. 2007;171:386–395. doi:10.2353/ajpath.2007.070152.
   PubMed Web of Science ®Google Scholar
• Xie X, Wang CY, Cao YX, Wang W, Zhuang R, Chen LH, Dang NN, Fang L, Jin BQ. Expression pattern of epithelial cell adhesion molecule on normal and malignant colon tissues. World J Gastroenterol. 2005;11:344–347. doi:10.3748/wjg.v11.i3.344.
   PubMed Web of Science ®Google Scholar
• Spizzo G, Fong D, Wurm M, Ensinger C, Obrist P, Hofer C, Mazzoleni G, Gastl G, Went P. EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysis. J Clin Pathol. 2011;64:415–420. doi:10.1136/jcp.2011.090274.
   PubMed Web of Science ®Google Scholar
• Ang WX, Li Z, Chi Z, Du SH, Chen C, Tay JC, Toh HC, Connolly JE, Xu XH, Wang S, et al. Intraperitoneal immunotherapy with T cells stably and transiently expressing anti-EpCAM CAR in xenograft models of peritoneal carcinomatosis. Oncotarget. 2017;8:13545–13559. doi:10.18632/oncotarget.14592.
   PubMed Web of Science ®Google Scholar
• Deng Z, Wu Y, Ma W, Zhang S, Zhang YQ. Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM. BMC Immunol. 2015;16:1. doi:10.1186/s12865-014-0064-x.
   PubMed Web of Science ®Google Scholar
• Zhang BL, Li D, Gong YL, Huang Y, Qin DY, Jiang L, Liang X, Yang X, Gou H-F, Wang Y-S, et al. Preclinical Evaluation of Chimeric Antigen Receptor-Modified T Cells Specific to Epithelial Cell Adhesion Molecule for Treating Colorectal Cancer. Hum Gene Ther. 2019;30:402–412. doi:10.1089/hum.2018.229.
   PubMed Web of Science ®Google Scholar
• EpCAM CAR-T for Treatment of Nasopharyngeal Carcinoma and Breast Cancer. [accessed 2019 Sep 30]. ClinicalTrials.gov: ClinicalTrials.gov
   Google Scholar
• Intraperitoneal Infusion of EpCAM CAR-T Cell in Advanced Gastric Cancer With Peritoneal Metastasis (WCH-GC-CART). [accessed 2019 Sep 30]. ClinicalTrials.gov: ClinicalTrials.gov
   Google Scholar
• A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer (CARTEPC). [accessed 2019 Sep 30]. ClinicalTrials.gov: ClinicalTrials.gov
   Google Scholar
• Study Evaluating the Efficacy and Safety With CAR-T for Liver Cancer (EECLC). [accessed 2019 Sep 30]. ClinicalTrials.gov: ClinicalTrials.gov
   Google Scholar
• Study Evaluating the Efficacy and Safety With CAR-T for Stomach Cancer (EECSC). [accessed 2019 Sep 30]. ClinicalTrials.gov: ClinicalTrials.gov
   Google Scholar
• Gross G, Eshhar Z. Therapeutic Potential of T Cell Chimeric Antigen Receptors (CARs) in Cancer Treatment: counteracting Off-Tumor Toxicities for Safe CAR T Cell Therapy. Annu Rev Pharmacol Toxicol. 2016;56:59–83. doi:10.1146/annurev-pharmtox-010814-124844.
   PubMed Web of Science ®Google Scholar
• Farr A, Nelson A, Truex J, Hosier S. Epithelial heterogeneity in the murine thymus: a cell surface glycoprotein expressed by subcapsular and medullary epithelium. J Histochem Cytochem. 1991;39:645–653. doi:10.1177/39.5.2016514.
   PubMed Web of Science ®Google Scholar
• Sampson JH, Choi BD, Sanchez-Perez L, Suryadevara CM, Snyder DJ, Flores CT, Schmittling RJ, Nair SK, Reap EA, Norberg PK, et al. EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss. Clin Cancer Res. 2014;20:972–984. doi:10.1158/1078-0432.CCR-13-0709.
   PubMed Web of Science ®Google Scholar
• Hartmann J, Schussler-Lenz M, Bondanza A, Buchholz CJ. Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts. EMBO Mol Med. 2017;9:1183–1197. doi:10.15252/emmm.201607485.
   PubMed Web of Science ®Google Scholar
• Kueberuwa G, Kalaitsidou M, Cheadle E, Hawkins RE, Gilham DE. CD19 CAR T Cells Expressing IL-12 Eradicate Lymphoma in Fully Lymphoreplete Mice through Induction of Host Immunity. Mol Ther Oncolytics. 2018;8:41–51. doi:10.1016/j.omto.2017.12.003.
   PubMed Web of Science ®Google Scholar
• Wada S, Yoshimura K, Hipkiss EL, Harris TJ, Yen HR, Goldberg MV, Grosso JF, Getnet D, Demarzo AM, Netto GJ, et al. Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model. Cancer Res. 2009;69:4309–4318. doi:10.1158/0008-5472.CAN-08-4102.
   PubMed Web of Science ®Google Scholar
• Cheadle EJ, Hawkins RE, Batha H, Rothwell DG, Ashton G, Gilham DE. Eradication of established B-cell lymphoma by CD19-specific murine T cells is dependent on host lymphopenic environment and can be mediated by CD4+ and CD8+ T cells. J Immunother. 2009;32:207–218. doi:10.1097/CJI.0b013e318194a921.
   PubMed Web of Science ®Google Scholar
• Lowe KL, Mackall CL, Norry E, Amado R, Jakobsen BK, Binder G. Fludarabine and neurotoxicity in engineered T-cell therapy. Gene Ther. 2018;25:176–191. doi:10.1038/s41434-018-0019-6.
   PubMed Web of Science ®Google Scholar
• Lamers CH, Sleijfer S, Vulto AG, Kruit WH, Kliffen M, Debets R, Gratama JW, Stoter G, Oosterwijk E. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol. 2006;24:e20–2. doi:10.1200/JCO.2006.05.9964.
   PubMedGoogle Scholar
• Hombach A, Hombach AA, Abken H. Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc ‘spacer’ domain in the extracellular moiety of chimeric antigen receptors avoids ‘off-target’ activation and unintended initiation of an innate immune response. Gene Ther. 2010;17:1206–1213. doi:10.1038/gt.2010.91.
   PubMed Web of Science ®Google Scholar
• Drent E, Themeli M, Poels R, de Jong-korlaar R, Yuan H, de Bruijn J, Martens ACM, Zweegman S, van de Donk NWCJ, Groen RWJ, et al. A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization. Mol Ther. 2017;25:1946–1958. doi:10.1016/j.ymthe.2017.04.024.
   PubMed Web of Science ®Google Scholar
• Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A, Sivertsson Å, Kampf C, Sjöstedt E, Asplund A, et al. Proteomics. Tissue-based map of the human proteome. Science. 2015 Jan 23;347(6220):1260419. doi:10.1126/science.1260419.
   PubMed Web of Science ®Google Scholar
• Bastian F, Parmentier G, Roux J, Moretti S, Laudet V, Robinson-Rechavi M. Mouse tissue expression of EpCAM. Mouse tissue expression of EpCAM: Bgee. New York (NY): Springer Nature; 2008.
   Google Scholar
• Visioni A, Kim M, Wilfong C, Blum A, Powers C, Fisher D, Gabriel E, Skitzki J. Intra-arterial Versus Intravenous Adoptive Cell Therapy in a Mouse Tumor Model. J Immunother. 2018;41:313–318. doi:10.1097/CJI.0000000000000235.
   PubMed Web of Science ®Google Scholar
• Gan HK, Cvrljevic AN, Johns TG. The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered. Febs J. 2013;280:5350–5370. doi:10.1111/febs.12393.
   PubMed Web of Science ®Google Scholar
• Sun S, Hao H, Yang G, Zhang Y, Fu Y. Immunotherapy with CAR-Modified T Cells: toxicities and Overcoming Strategies. J Immunol Res. 2018;2018:2386187. doi:10.1155/2018/2386187.
   PubMed Web of Science ®Google Scholar
• Went PT, Lugli A, Meier S, Bundi M, Mirlacher M, Sauter G, Dirnhofer S. Frequent EpCam protein expression in human carcinomas. Hum Pathol. 2004;35:122–128. doi:10.1016/j.humpath.2003.08.026.
   PubMed Web of Science ®Google Scholar
• Gentile ME, King IL. Blood and guts: the intestinal vasculature during health and helminth infection. PLoS Pathog. 2018;14:e1007045. doi:10.1371/journal.ppat.1007045.
   PubMed Web of Science ®Google Scholar
• Ungaro F, Tacconi C, D’Alessio S. Beyond Intestinal Barrier: the Blood Endothelium as a Second Wall of Defense Against Bacterial Invasion. Gastroenterology. 2016;150:1678–1680. doi:10.1053/j.gastro.2016.04.024.
   PubMedGoogle Scholar
• Spadoni I, Zagato E, Bertocchi A, Paolinelli R, Hot E, Di Sabatino A, Caprioli F, Bottiglieri L, Oldani A, Viale G, et al. A gut-vascular barrier controls the systemic dissemination of bacteria. Science (New York, NY). 2015;350:830–834. doi:10.1126/science.aad0135.
   Google Scholar
• Barrowcliffe MP, Jones JG. Solute permeability of the alveolar capillary barrier. Thorax. 1987;42:1–10. doi:10.1136/thx.42.1.1.
   PubMed Web of Science ®Google Scholar
• Bernhard H, Neudorfer J, Gebhard K, Conrad H, Hermann C, Nährig J, Fend F, Weber W, Busch DH, Peschel C, et al. Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer. Cancer Immunology, Immunotherapy: CII. 2008;57:271–280. doi:10.1007/s00262-007-0355-7.
   PubMed Web of Science ®Google Scholar
• Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol. 2000;164:6166–6173. doi:10.4049/jimmunol.164.12.6166.
   PubMed Web of Science ®Google Scholar
• Hsieh CS, Macatonia SE, O’Garra A, Murphy KM. T cell genetic background determines default T helper phenotype development in vitro. J Exp Med. 1995;181:713–721. doi:10.1084/jem.181.2.713.
   PubMed Web of Science ®Google Scholar